Targeting the prostaglandin D2 receptors DP1 and CRTH2 for treatment of inflammation

Frontiers in Medicinal Chemistry

Volumn 5, Issue 1, 2010, Pages 350-380

  Ulven, Trond ^a   Kostenis, Evi ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Allergy; Asthma; CRTH2; DP1; DP2; Drug discovery; Inflammation; Prostaglandin D2

Indexed keywords

EID: 84880160927     PISSN: 15672042     EISSN: 18755763     Source Type: Book Series    
DOI: None     Document Type: Review

References (168)

1. O'Brien, J. Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am. J. Gastroenterol., 2000, 95, 1859-1861.
2. Babu, K. S.; Salvi, S. S. Aspirin and asthma. Chest, 2000, 118, 1470-1476.
3. Dogne, J. M.; Supuran, C. T.; Pratico, D. Adverse cardiovascular effects of the coxibs. J. Med. Chem., 2005, 48, 2251-2257.
4. 2in patients with systemic mastocytosis. N. Engl. J. Med., 1980, 303, 1400-1404.
5. 2generation after activation of rat and human mast cells with anti-IgE. J. Immunol., 1982, 129, 1627-1631.
6. 2into human airways during acute antigen challenge. N. Engl. J. Med., 1986, 315, 800-804.
7. 2in normal and asthmatic men. N. Engl. J. Med., 1984, 311, 209-213.
8. 2causes accumulation of eosinophils in the lumen of the dog trachea. J. Appl. Physiol., 1989, 67, 959-962.
9. 2from human skin in vivo and in vitro during immediate allergic reactions. Br. J. Pharmacol., 1988, 94, 773-780.
10. Hata, A. N.; Breyer, R. M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther., 2004, 103, 147-166.
11. Fujitani, Y.; Kanaoka, Y.; Aritake, K.; Uodome, N.; Okazaki-Hatake, K.; Urade, Y. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J. Immunol., 2002, 168, 443-449.
12. Noguchi, E.; Shibasaki, M.; Kamioka, M.; Yokouchi, Y.; Yamakawa-Kobayashi, K.; Hamaguchi, H.; Matsui, A.; Arinami, T. New polymorphisms of haematopoietic prostaglandin D synthase and human prostanoid DP receptor genes. Clin. Exp. Allergy., 2002, 32, 93-96.
13. Miwa, Y.; Takiuchi, S.; Kamide, K.; Yoshii, M.; Horio, T.; Tanaka, C.; Banno, M.; Miyata, T.; Sasaguri, T.; Kawano, Y. Identification of gene polymorphism in lipocalin-type prostaglandin D synthase and its association with carotid atherosclerosis in Japanese hypertensive patients. Biochem. Biophys. Res. Commun., 2004, 322, 428-433.
14. 2receptors DP and CRTH2 for treatment of inflammation. Curr. Top. Med. Chem., 2006, 6, 1427-1444.
15. Yasui, K.; Arimura, A. Eicosanoid antagonists. In Eicosanoids; Curtis-Prior, P., Ed.; John Wiley & Sons Ltd.: Chichester, UK, 2004; pp 163-178.
16. Mitsumori, S. Recent progress in work on PGD(2) antagonists for drugs targeting allergic diseases. Curr. Pharm. Des., 2004, 10, 3533-3538.
17. Ly, T. W.; Bacon, K. B. Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview. Exp. Opin. Investig. Drugs, 2005, 14, 769-773.
18. 1and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug. Discov., 2007, 6, 313-325.
19. Caramori, G.; Groneberg, D.; Kazuhiro, I.; Casolari, P.; Adcock, I. M.; Papi, A. New drugs targeting Th2 lymphocytes in asthma. J. Occup. Med. Toxicol., 2008, 3, S6.
20. 1and CRTH2 in promoting allergic responses. Br. J. Pharmacol., 2008, 153, S191-S199.
21. Hirata, M.; Kakizuka, A.; Aizawa, M.; Ushikubi, F.; Narumiya, S. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc. Natl. Acad. Sci. USA, 1994, 91, 11192-11196.
22. Boie, Y.; Sawyer, N.; Slipetz, D. M.; Metters, K. M.; Abramovitz, M. Molecular cloning and characterization of the human prostanoid DP repector. J. Biol. Chem., 1995, 270, 18910-18916.
23. 2receptors in human platelets. J. Pharmacol. Exp. Ther., 1979, 210, 134-140.
24. Walch, L.; Labat, C.; Gascard, J. P.; de Montpreville, V.; Brink, C.; Norel, X. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br. J. Pharmacol., 1999, 126, 859-866.
25. Norel, X.; Walch, L.; Labat, C.; Gascard, J. P.; Dulmet, E.; Brink, C. Prostanoid receptors involved in the relaxation of human bronchial preparations. Br. J. Pharmacol., 1999, 126, 867-872.
26. Woodward, D. F.; Spada, C. S.; Hawley, S. B.; Williams, L. S.; Protzman, C. E.; Nieves, A. L. Further studies on ocular responses to DP receptor stimulation. Eur. J. Pharmacol., 1993, 230, 327-333.
27. Mizoguchi, A.; Eguchi, N.; Kimura, K.; Kiyohara, Y.; Qu, W. M.; Huang, Z. L.; Mochizuki, T.; Lazarus, M.; Kobayashi, T.; Kaneko, T.; Narumiya, S.; Urade, Y.; Hayaishi, O. Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep. Proc. Natl. Acad. Sci. USA, 2001, 98, 11674-11679.
28. 2as a mediator of allergic asthma. Science, 2000, 287, 2013-2017.
29. Arimura, A.; Yasui, K.; Kishino, J.; Asanuma, F.; Hasegawa, H.; Kakudo, S.; Ohtani, M.; Arita, H. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J. Pharmacol. Exp. Ther., 2001, 298, 411-419.
30. 2receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14, 4891-4895.
31. 2inhibits airway dentritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J. Immunol., 2003, 171, 3936-3940.
32. Hammad, H.; Kool, M.; Soullie, T.; Narumiya, S.; Trottein, F.; Hoogsteden, H. C.; Lambrecht, B. N. Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J. Exp. Med., 2007, 204, 357-367.
33. Angeli, W.; Staumont, D.; Charbonnier, A. S.; Hammad, H.; Gosset, P.; Pichavant, M.; Lambrecht, B. N.; Capron, M.; Dombrowicz, D.; Trottein, F. Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses. J. Immunol., 2004, 172, 3822-3829.
34. 2receptor DP2/CRTH2 increases allergic inflammation in mouse. J. Immunol., 2005, 174, 3703-3708.
35. Arai, I.; Takano, N.; Hashimoto, Y.; Futaki, N.; Sugimoto, M.; Takahashi, N.; Inoue, T.; Nakaike, S. Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur. J. Pharmacol., 2004, 505, 229-235.
36. Oguma, T.; Palmer, L. J.; Birben, E.; Sonna, L. A.; Asano, K.; Lilly, C. M. Role of prostanoid DP receptor variants in susceptibility to asthma. N. Engl. J. Med., 2004, 351, 1752-1763.
37. Kabashima, K.; Narumiya, S. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot. Essent. Fatty Acids, 2003, 69, 187-194.
38. 2is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood, 2001, 98, 1942-1948.
39. Kostenis, E.; Ulven, T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol. Med., 2006, 12, 148-158.
40. Rangachari, P. K.; Betti, P. A.; Prior, E. T.; Roberts, L. J. Effects of a selective DP receptor agonist (BW 245C) and antagonist (BW A868C) on the canine colonic epithelium-and argument for a different DP receptor. J. Pharmacol. Exp. Ther., 1995, 275, 611-617.
41. 2and its analogues. Br. J. Pharmacol., 1985, 85, 367-375.
42. Marchese, A.; Sawzdargo, M.; Nguyen, T.; Cheng, R.; Heng, H. H. Q.; Nowak, T.; Im, D. S.; Lynch, K. R.; George, S. R.; O'Dowd, B. F. Discovery of three novel orphan G-protein-coupled receptors. Genomics, 1999, 56, 12-21.
43. Nagata, K.; Tanaka, K.; Ogawa, K.; Kemmotsu, K.; Imai, T.; Yoshie, O.; Abe, H.; Tada, K.; Nakamura, M.; Sugamura, K.; Takano, S. Selective expression of a novel surface molecule by human Th2 cells in vivo. J. Immunol., 1999, 162, 1278-1286.
44. Nagata, K.; Hirai, H.; Tanaka, K.; Ogawa, K.; Aso, T.; Sugamura, K.; Nakamura, M.; Takano, S. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett., 1999, 459, 195-199.
45. 2selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med., 2001, 193, 255-261.
46. Gervais, F. G.; Cruz, R. P. G.; Chateauneuf, A.; Gale, S.; Sawyer, N.; Nantel, F.; Metters, K. M.; O'Neill, G. P. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD(2) receptors CRTH2 and DP. J. Allergy Clin. Immunol., 2001, 108, 982-988.
47. Chevalier, E.; Stock, J.; Fisher, T.; Dupont, M.; Fric, M.; Fargeau, H.; Leport, M.; Soler, S.; Fabien, S.; Pruniaux, M. P.; Fink, M.; Bertrand, C. P.; McNeish, J.; Li, B. Y. Cutting edge: chemoattractant receptorhomologous molecule expressed on TH2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J. Immunol., 2005, 175, 2056-2060.
48. Herrick, C. A.; Bottomly, K. To respond or not to respond: T cells in allergic asthma. Nat. Rev. Immunol., 2003, 3, 405-412.
49. Lee, J. J.; Dimina, D.; Macias, M. P.; Ochkur, S. I.; McGarry, M. P.; O'Neill, K. R.; Protheroe, C.; Pero, R.; Nguyen, T.; Cormier, S. A.; Lenkiewicz, E.; Colbert, D.; Rinaldi, L.; Ackerman, S. J.; Irvin, C. G.; Lee, N. A. Defining a link with asthma in mice congenitally deficient in eosinophils. Science, 2004, 305, 1773-1776.
50. Humbles, A. A.; Lloyd, C. M.; McMillan, S. J.; Friend, D. S.; Xanthou, G.; McKenna, E. E.; Ghiran, S.; Gerard, N. P.; Yu, C. N.; Orkin, S. H.; Gerard, C. A critical role for eosinophils in allergic airways remodeling. Science, 2004, 305, 1776-1779.
51. Schroeder, J. T. Basophils: beyond effector cells of allergic inflammation. Adv. Immunol., 2009; Vol. 101, 123-161.
52. Yoshimura-Uchiyama, C.; Iikura, M.; Yamaguchi, M.; Nagase, H.; Ishii, A.; Matsushima, K.; Yamamoto, K.; Shichijo, M.; Bacon, K. B.; Hirai, K. Differential modulation of human basophil functions through prostaglandin D-2 receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2. Clin. Exp. Allergy., 2004, 34, 1283-1290.
53. Huang, J. L.; Gao, P. S.; Mathias, R. A.; Yao, T. C.; Chen, L. C.; Kuo, M. L.; Hsu, S. C.; Plunkett, B.; Togias, A.; Barnes, K. C.; Stellato, C.; Beaty, T. H.; Huang, S. K. Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. Hum. Mol. Genet., 2004, 13, 2691-2697.
54. Wang, J. H.; Xu, Y. C.; Zhao, H.; Sui, H.; Liang, H. Y.; Jiang, X. F. Genetic variations in chemoattractant receptor expressed on Th2 cells (CRTH2) is associated with asthma susceptibility in Chinese children. Mol. Biol. Rep., 2009, 36, 1549-1553.
55. Cameron, L.; Depner, M.; Kormann, M.; Klopp, N.; Illig, T.; von Mutius, E.; Kabesch, M. Genetic variation in CRTh2 influences development of allergic phenotypes. Allergy, 2009, 64, 1478-1485.
56. 2receptors DP and CRTH2 in human nasal mucosa. Prostaglandins Other Lipid Mediat., 2004, 73, 87-101.
57. 2receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis. J. Invest. Dermatol., 2002, 119, 609-616.
58. Venet, F.; Lepape, A.; Debard, A. L.; Bienvenu, J.; Bohe, J.; Monneret, G. The Th2 response as monitored by CRTH2 or CCR3 expression is severely decreased during septic shock. Clin. Immunol., 2004, 113, 278-284.
59. 2induces chemotaxis in eosinophils via its receptor CRTH2 and eosinophils may cause severe ocular inflammation in patients with allergic conjunctivitis. Cornea, 2005, 24, S66-S70.
60. 2by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. J. Bone Miner. Res., 2005, 20, 672-681.
61. 2receptor, CRTH2. Br. J. Pharmacol., 2002, 137, 1163-1172.
62. 2is a potent and selective CRTH2 receptor agonist and causes activation of human eosinophils and Th2 lymphocytes. Prostaglandins Other Lipid Mediat., 2005, 75, 153-167.
63. 2and its stereoisomer PGF2222are novel agonists of the chemoattractant receptor, CRTH2. FEBS Lett., 2006, 580, 373-379.
64. 2, from the bone marrow and primes eosinophils for chemotaxis. J. Immunol., 2003, 170, 4752-4758.
65. Kobayashi, Y.; Ueki, S.; Mahemuti, G.; Chiba, T.; Oyamada, H.; Saito, N.; Kanda, A.; Kayaba, H.; Chihara, J. Physiological levels of 15-deoxy-CC12,14-prostaglandin J2 prime eotaxin-induced chemotaxis on human eosinophils through peroxisome proliferator-activated receptor-gamma lipation. J. Immunol., 2005, 175, 5744-5750.
66. Wright, D. H.; Metters, K. M.; Abramovitz, M.; Ford-Hutchinson, A. W. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br. J. Pharmacol., 1998, 123, 1317-1324.
67. Bohm, E.; Sturm, G. J.; Weiglhofer, I.; Sandig, H.; Shichijo, M.; McNamee, A.; Pease, J. E.; Kollroser, M.; Peskar, B. A.; Heinemann, A. 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J. Biol. Chem., 2004, 279, 7663-7670.
68. Caldwell, A. G.; Harris, C. J.; Stepney, R.; Whittaker, N. Hydantoin prostaglandin analog, potent and selective inhibitors of platelet aggregation. J. Chem. Soc., Chem. Commun., 1979, 561-562.
69. Arai, I.; Takaoka, A.; Hashimoto, Y.; Honma, Y.; Koizumi, C.; Futaki, N.; Sugimoto, M.; Takahashi, N.; Inoue, T.; Nakanishi, Y.; Sakurai, T.; Tanami, T.; Yagi, M.; Ono, N.; Nakaike, S. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice. Eur. J. Pharmacol., 2007, 556, 207-214.
70. 2is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils. J. Pharmacol. Exp. Ther., 2003, 304, 349-355.
71. 2receptor agonist. Bioorg. Med. Chem. Lett., 2005, 15, 1873-1876.
72. 2on human eosinophils and basophils. J. Pharmacol. Exp. Ther., 2007, 320, 173-179.
73. 2receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats. J. Pharmacol. Exp. Ther., 2005, 313, 64-69.
74. 2receptor, CRTH2. J. Immunol., 2002, 168, 981-985.
75. Stubbs, V. E. L.; Schratl, P.; Hartnell, A.; Williams, T. J.; Peskar, B. A.; Heinemann, A.; Sabroe, I. Indomethacin causes prostaglandin D-2-like and eotaxin-like selective responses in eosinophils and basophils. J. Biol. Chem., 2002, 277, 26012-26020.
76. 2receptor CRTH2. Mol. Pharmacol., 2005, 67, 640-647.
77. 2receptor CRTH2. J. Biol. Chem., 2005, 280, 32442-32451.
78. Gervais, F. G.; Morello, J. P.; Beaulieu, C.; Sawyer, N.; Denis, D.; Greig, G.; Malebranche, A. D.; O'Neill, G. P. Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol. Pharmacol., 2005, 67, 1834-1839.
79. 2. J. Pharmacol. Exp. Ther., 2005, 314, 244-251.
80. Giles, H.; Leff, P.; Bolofo, M. L.; Kelly, M. G.; Robertson, A. D. The classification of prostaglandin DPreceptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br. J. Pharmacol., 1989, 96, 291-300.
81. 2receptor, DP, in eosinophil trafficking. J. Immunol., 2007, 179, 4792-4799.
82. Keery, R. J.; Lumley, P. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br. J. Pharmacol., 1988, 94, 745-754.
83. Tsuri, T.; Honma, T.; Hiramatsu, Y.; Okada, T.; Hashizume, H.; Mitsumori, S.; Inagaki, M.; Arimura, A.; Yasui, K.; Asanuma, F.; Kishino, J.; Ohtani, M. Bicyclo 2.2.1 heptane and 6,6-dimethylbicyclo 3.1.1 heptane derivatives: Orally active, potent, and selective prostaglandin D-2 receptor antagonists. J. Med. Chem., 1997, 40, 3504-3507.
84. Mitsumori, S.; Tsuri, T.; Honma, T.; Hiramatsu, Y.; Okada, T.; Hashizume, H.; Inagaki, M.; Arimura, A.; Yasui, K.; Asanuma, F.; Kishino, J.; Ohtani, M. Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D-2 receptor antagonists. 1. Bicyclo 2.2.1 heptane derivatives. J. Med. Chem., 2003, 46, 2436-2445.
85. Mitsumori, S.; Tsuri, T.; Honma, T.; Hiramatsu, Y.; Okada, T.; Hashizume, H.; Kida, S.; Inagaki, M.; Arimura, A.; Yasui, M.; Asanuma, F.; Kishino, J.; Ohtani, M. Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D-2 receptor antagonists. 2. 6,6-dimethylbicyclo 3.1.1 heptane derivatives. J. Med. Chem., 2003, 46, 2446-2455.
86. 2receptor antagonist modifies experimental asthma in sheep. Clin. Exp. Allergy., 2009, 39, 1404-1414.
87. 2receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14, 4557-4562.
88. 2receptor antagonist: discovery of highly potent antagonists. Bioorg. Med. Chem., 2004, 12, 4685-4700.
89. 2receptor antagonists. Bioorg. Med. Chem., 2004, 12, 5361-5378.
90. Iwahashi, M.; Naganawa, A.; Nishiyama, T.; Nagase, T.; Kobayashi, K.; Nambu, F. Indole derivative compounds drugs containing the compounds as the active ingredient. WO 2004078719, 2004.
91. Beaulieu, C.; Wang, Z. Y.; Denis, D.; Greig, G.; Lamontagne, S.; O'Neill, G.; Slipetz, D.; Wang, J. Benzimidazoles as new potent and selective DP antagonists for the treatment of allergic rhinitis. Bioorg. Med. Chem. Lett., 2004, 14, 3195-3199.
92. 2receptor antagonists for treatment of allergic rhinitis, nasal congestion, and asthma. WO 2002094830, 2002.
93. Leblanc, Y.; Dufresne, C.; Roy, P. Pyridopyrrolizine and pyridoindolizine derivatives. WO 2004039807, 2004.
94. 2receptor antagonists. WO 2001079169, 2001.
95. Cheng, K.; Waters, M. G.; Metters, K. M.; O'Neill, G. Method of treating atherosclerosis, dyslipidemias and related conditions. US 2004229844, 2004.
96. 2receptor antagonist, [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc yclopenta[b]indol-3-yl]-acetic acid (MK-0524). J. Med. Chem., 2007, 50, 794-806.
97. 2receptor antagonist, in humans. Drug. Metab. Dispos., 2007, 35, 1196-1202.
98. 2receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. USA, 2006, 103, 6682-6687.
99. Lai, E.; De Lepeleire, I.; Crumley, T. M.; Liu, F.; Wenning, L. A.; Michiels, N.; Vets, E.; O'Neill, G.; Wagner, J. A.; Gottesdiener, K. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D-2 receptor subtype 1. Clin. Pharmacol. Ther., 2007, 81, 849-857.
100. Philip, G.; van Adelsberg, J.; Loeys, T.; Liu, N.; Wong, P.; Lai, E.; Dass, S. B.; Reiss, T. F. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J. Allergy Clin. Immunol., 2009, 124, 942-948.
101. Aizawa, H.; Shigyo, M.; Nogami, H.; Hirose, T.; Hara, N. BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. Chest, 1996, 109, 338-342.
102. Ohkubo, K.; Gotoh, M. Effect of ramatroban, a thromboxane A2 antagonist, in the treatment of perennial allergic rhinitis. Allergol. Int., 2003, 52, 131-138.
103. Rosentreter, U.; Boshagen, H.; Seuter, F.; Perzborn, E.; Fiedler, V. B. Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropanoic acid and comparison with its enantiomer. Arzneim.-Forsch., 1989, 39-2, 1519-1521.
104. 2)-induced bronchoconstriction in the anaesthetised guinea pig. Ann. N.Y. Acad. Sci., 1991, 629, 399-401.
105. 2-induced bronchoconstriction in the guinea-pig. Br. J. Pharmacol., 1991, 104, 596-602.
106. 2-induced eosinophil migration in vitro. J. Pharmacol. Exp. Ther., 2003, 305, 347-352.
107. Dogne, J. M.; de Leval, X.; Benoit, P.; Rolin, S.; Pirotte, B.; Masereel, B. Therapeutic potential of thromboxane inhibitors in asthma. Exp. Opin. Investig. Drugs, 2002, 11, 275-281.
108. 2receptor antagonist ramatroban in animals-1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs. Arzneim.-Forsch., 1997, 47, 928-938.
109. Shichijo, M.; Sugimoto, H.; Nagao, K.; Inbe, H.; Encinas, J. A.; Takeshita, K.; Bacon, K. B.; Gantner, F. Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats. J. Pharmacol. Exp. Ther., 2003, 307, 518-525.
110. 2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J. Pharmacol. Exp. Ther., 2005, 312, 954-960.
111. Takeshita, K.; Yamasaki, T.; Nagao, K.; Sugimoto, H.; Shichijo, M.; Gantner, F.; Bacon, K. B. CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation. Int. Immunol., 2004, 16, 947-959.
112. 2plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J. Immunol., 2006, 177, 2621-2629.
113. Ulven, T.; Kostenis, E. Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J. Med. Chem., 2005, 48, 897-900.
114. 2receptor CRTH2. Mol. Pharmacol., 2006, 69, 1441-1453.
115. Royer, J. F.; Schratl, P.; Lorenz, S.; Kostenis, E.; Ulven, T.; Schuligoi, R.; Peskar, B. A.; Heinemann, A. A novel antagonist of CRTH2 blocks eosinophil release from bone marrow, chemotaxis and respiratory burst. Allergy, 2007, 62, 1401-1409.
116. 2receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir. Res., 2007, 8, 16.
117. Wang, Z. Preparation of indole derivatives as CRTH2 receptor antagonists. WO 2007019675, 2007.
118. 2receptor DP2 with efficacy in a murine model of allergic rhinitis. Bioorg. Med. Chem. Lett., 2009, 19, 4647-4651.
119. Robarge, M. J.; Bom, D. C.; Tumey, L. N.; Varga, N.; Gleason, E.; Silver, D.; Song, J. P.; Murphy, S. M.; Ekema, G.; Doucette, C.; Hanniford, D.; Palmer, M.; Pawlowski, G.; Danzig, J.; Loftus, M.; Hunady, K.; Sherf, B. A.; Mays, R. W.; Stricker-Krongrad, A.; Brunden, K. R.; Harrington, J. J.; Bennani, Y. L. Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists. Bioorg. Med. Chem. Lett., 2005, 15, 1749-1753.
120. 2receptor antagonists. WO 2003097042, 2003.
121. 2receptor antagonists. WO 2003097598, 2003.
122. 2receptor CRTH2. Bioorg. Med. Chem. Lett., 2007, 17, 5924-5927.
123. Baxter, A.; Steele, J.; Teague, S. Use of indole-3-acetic acids in the treatment of asthma, COPD and other diseases. WO 2003066046, 2003.
124. Baxter, A.; Steele, J.; Teague, S. Use of indole-3-acetic acids in the treatment of asthma, COPD and other diseases WO 2003066047, 2003.
125. Birkinshaw, T.; Bonnert, R.; Cook, A.; Rasul, R.; Sanganee, H.; Teague, S. Novel substituted indols. WO 2003101981, 2003.
126. Bonnert, R.; Brough, S.; Cook, T.; Dickinson, M.; Rasul, R.; Sanganee, H.; Teague, S. Novel substituted indoles. WO 2003101961, 2003.
127. Bonnert, R.; Dickinson, M.; Rasul, R.; Sanganee, H.; Teague, S. Indole-3-sulphur derivatives and their use in the treatment of respiratory disorders. WO 2004007451, 2004.
128. Bonnert, R. V.; Cook, A. R.; Luker, T. J.; Mohammed, R. T.; Thom, S. Substituted indoleacetic acids as CRTh2 receptor ligands for treating respiratory diseases. WO 2005019171, 2005.
129. Bonnert, R.; Rasul, R. Novel substituted 3-sulfur indoles. WO 2004106302, 2004.
130. 2) receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 4287-4290.
131. 2blocks the locomotion of eosinophils and basophils. Eur. J. Clin. Invest., 2008, 38, 663-671.
132. Bonnert, R. V.; Mohammed, R. T.; Teague, S. 1-Acetic acid-indole,-indazole, and-benzimidazole derivatives for the treatment of respiratory disorders. WO 2005054232, 2005.
133. 2receptor CRTH2. J. Med. Chem., 2005, 48, 6174-6177.
134. Middlemiss, D.; Ashton, M. R.; Boyd, E. A.; Brookfield, F. A.; Armer, R. E. Compounds having CRTH2 antagonist activity. WO 2005040114, 2005.
135. Middlemiss, D.; Ashton, M. R.; Boyd, E. A.; Brookfield, F. A.; Armer, R. E. Compounds with PGD2 antagonist activity. WO 2005040112, 2005.
136. Bala, K.; Leblanc, C.; Sandham, D. A.; Turner, K. L.; Watson, S. J.; Brown, L. N.; Cox, B. Pyrrolopyridines as CRTh2 receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy. WO 2005123731, 2005.
137. Sandham, D. A.; Adcock, C.; Bala, K.; Barker, L.; Brown, Z.; Dubois, G.; Budd, D.; Cox, B.; Fairhurst, R. A.; Furegati, M.; Leblanc, C.; Manini, J.; Profit, R.; Reilly, J.; Stringer, R.; Schmidt, A.; Turner, K. L.; Watson, S. J.; Willis, J.; Williams, G.; Wilson, C. 7-Azaindole-3-acetic acid derivatives: Potent and selective CRTh2 receptor antagonists. Bioorg. Med. Chem. Lett., 2009, 19, 4794-4798.
138. Middlemiss, D.; Ashton, M. R.; Boyd, E. A.; Brookfield, F. A. Substituted indol-3-yl acetic acid derivatives. GB 2407318, 2005.
139. Middlemiss, D.; Ashton, M. R.; Boyd, E. A.; Brookfield, F. A. Use of CRTH2 antagonist compounds in therapy. WO 2005044260, 2005.
140. Norman, P. Indole-based CRTH2 antagonists. Expert Opin. Ther. Pat., 2005, 15, 1817-1823.
141. Fecher, A.; Fretz, H.; Hilpert, K.; Riederer, M. Indole-1-yl-acetic acid derivatives. WO 2005094816, 2005.
142. Crosignani, S.; Page, P.; Missotten, M.; Colovray, V.; Cleva, C.; Arrighi, J. F.; Atherall, J.; Macritchie, J.; Martin, T.; Humbert, Y.; Gaudet, M.; Pupowicz, D.; Maio, M.; Pittet, P. A.; Golzio, L.; Giachetti, C.; Rocha, C.; Bernardinelli, G.; Filinchuk, Y.; Scheer, A.; Schwarz, M. K.; Chollet, A. Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J. Med. Chem., 2008, 51, 2227-2243.
143. 2receptor CRTH2. Mol. Pharmacol., 2005, 68, 393-402.
144. Ghosh, S.; Elder, A. M.; Carson, K. G.; Sprott, K.; Harrison, S. PGD2 receptor antagonists for the treatment of inflammatory diseases. WO 2004032848, 2004.
145. 2receptor antagonists for the treatment of inflammatory diseases. WO 2005100321, 2005.
146. Kuhn, C.; Feru, F.; Bazin, M.; Awad, M.; Goldstein, S. W. A preparation of tetrahydroquinoline derivatives as CRTH2 antagonists. EP 1413306, 2004.
147. Kuhn, C.; Feru, F.; Bazin, M.; Awad, M.; Goldstein, S. W. Quinoline derivatives as CRTH2 antagonists. EP 1435356, 2004.
148. Awad, M. M. A.; Bazin, M.; Feru, F.; Goldstein, S. W.; Kuhn, C. F. Tetrahydroquinoline derivatives as CRTh2 antagonists. WO 2004035543, 2004.
149. Inman, W. D.; Liu, J.; Medina, J. C.; Miao, S.; Tang, H. L. Asthma and allergic inflammation modulators. WO 2005007094, 2005.
150. Liu, J. W.; Wang, Y. C.; Sun, Y.; Marshall, D.; Miao, S. C.; Tonn, G.; Anders, P.; Tocker, J.; Tang, H. L.; Medina, J. Tetrahydroquinoline derivatives as CRTH2 antagonists. Bioorg. Med. Chem. Lett., 2009, 19, 6840-6844.
151. Frimurer, T. M.; Ulven, T.; Elling, C. E.; Gerlach, L. O.; Kostenis, E.; Hogberg, T. A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg. Med. Chem. Lett., 2005, 15, 3707-3712.
152. Fu, Z.; Huang, X. A.; Liu, J.; Medina, J. C.; Schmitt, M. J.; Tang, L. H.; Wang, Y.; Xu, Q. Asthma and allergic inflammation modulators. WO 2004058164, 2004.
153. Liu, J. W.; Fu, Z.; Wang, Y. C.; Schmitt, M.; Huang, A.; Marshall, D.; Tonn, G.; Seitz, L.; Sullivan, T.; Tang, H. L.; Collins, T.; Medina, J. Discovery and optimization of CRTH2 and DP dual antagonists. Bioorg. Med. Chem. Lett., 2009, 19, 6419-6423.
154. Wie, L. T.; Koriyama, Y.; Yoshino, T.; Sato, H.; Tanaka, K.; Sugimoto, H.; Manabe, Y.; Bacon, K.; Urbahns, K. Pyrimidinylacetic acid derivatives, useful as CRTH2 antagonists. EP 1471057, 2004.
155. Ly, T.-W.; Yoshino, T.; Takekawa, Y.; Shintani, T.; Sugimoto, H.; Bacon, K. B.; Urbahns, K. Imidazo[1,2-c]pyrimidinylacetic acid derivatives. WO 2005073234, 2005.
156. Lukacs, N. W.; Berlin, A. A.; Franz-Bacon, K.; Sasik, R.; Sprague, L. J.; Ly, T. W.; Hardiman, G.; Boehme, S. A.; Bacon, K. B. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol., 2008, 295, L767-L779.
157. Bonnert, R.; Brough, S.; Davies, A.; Luker, T.; McInally, T.; Millichip, I.; Pairaudeau, G.; Patel, A.; Rasul, R.; Thom, S. Novel compounds. WO 2004089885, 2004.
158. Bonnert, R. V.; Patel, A.; Thom, S. Novel compounds. WO 2005018529, 2005.
159. Sandham, D. A.; Turner, K. L.; Leblanc, C. Preparation of substituted phenoxyacetic acids as CRTh2 receptor antagonists for treating inflammatory or allergic condition. WO 2005105727, 2005.
160. Sandham, D. A.; Aldcroft, C.; Baettig, U.; Barker, L.; Beer, D.; Bhalay, G.; Brown, Z.; Dubois, G.; Budd, D.; Bidlake, L.; Campbell, E.; Cox, B.; Everatt, B.; Harrison, D.; Leblanc, C. J.; Manini, J.; Profit, R.; Stringer, R.; Thompson, K. S.; Turner, K. L.; Tweed, M. F.; Walker, C.; Watson, S. J.; Whitebread, S.; Willis, J.; Williams, G.; Wilson, C. 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg. Med. Chem. Lett., 2007, 17, 4347-4350.
161. Ulven, T.; Frimurer, T.; Rist, O.; Kostenis, E.; Hoegberg, T.; Receveur, J.-M.; Grimstrup, M. CRTH2 receptor ligands for therapeutic use. WO 2005115382, 2005.
162. Ulven, T.; Receveur, J. M.; Grimstrup, M.; Rist, O.; Frimurer, T. M.; Gerlach, L. O.; Mathiesen, J. M.; Kostenis, E.; Uller, L.; Hogberg, T. Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J. Med. Chem., 2006, 49, 6638-6641.
163. Ulven, T.; Frimurer, T.; Rist, O.; Kostenis, E.; Hoegberg, T.; Receveur, J.-M.; Grimstrup, M. Substituted thiazoleacetic acids as CRTH2 receptor ligands. WO 2005116001, 2005.
164. Rist, Ø.; Grimstrup, M.; Receveur, J.-M.; Frimurer, T. M.; Ulven, T.; Kostenis, E.; Högberg, T. Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1. Bioorg. Med. Chem. Lett., 2010, 20, 1177-1180.
165. Grimstrup, M.; Rist, Ø.; Receveur, J.-M.; Frimurer, T. M.; Ulven, T.; Mathiesen, J. M.; Kostenis, E.; Högberg, T. Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2. Bioorg. Med. Chem. Lett., 2010, 20, 1181-1185.
166. Ulven, T.; Frimurer, T.; Rist, O.; Kostenis, E.; Hoegberg, T.; Receveur, J.-M.; Grimstrup, M. Thiazoleand pyrimidineacetic acid derivatives as CRTH2 receptor ligands, their preparation, pharmaceutical compositions, and use in therapy. WO 2007062677, 2007.
167. Grimstrup, M.; Receveur, J.-M.; Rist, Ø.; Frimurer, T. M.; Nielsen, P. A.; Mathiesen, J. M.; Högberg, T. Exploration of SAR features by modifications of thiazoleacetic acids as CRTH2 antagonists. Bioorg. Med. Chem. Lett., 2010, 20(5), 1638-1641.
168. Ulven, T.; Frimurer, T.; Rist, O.; Kostenis, E.; Hoegberg, T. CRTH2 receptor ligands for therapeutic use. WO 2005115374, 2005.